Alnylam Pharmaceuticals (ALNY) Earns News Sentiment Score of 0.22
News coverage about Alnylam Pharmaceuticals (NASDAQ:ALNY) has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a news impact score of 0.22 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.0804027220238 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Alnylam Pharmaceuticals, Inc. (ALNY) Earns “Buy” Rating from Jefferies Group LLC (americanbankingnews.com)
- Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You? (finance.yahoo.com)
- Nomura bearish on Alnylam; sees 28% downside risk – Seeking Alpha (seekingalpha.com)
- Alnylam Pharmaceuticals, Inc. (ALNY) Research Coverage Started at Instinet (americanbankingnews.com)
- Alnylam Pharmaceuticals, Inc. (ALNY) Coverage Initiated at Nomura (americanbankingnews.com)
A number of research analysts recently commented on the company. ValuEngine raised Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BMO Capital Markets reissued an “outperform” rating and issued a $99.00 price target (down from $105.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 6th. Barclays PLC reissued an “overweight” rating and issued a $105.00 price target (up from $80.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Needham & Company LLC reissued a “buy” rating and issued a $85.00 price target (down from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $102.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, June 22nd. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $81.11.
Alnylam Pharmaceuticals (ALNY) opened at 76.00 on Tuesday. The stock’s 50 day moving average price is $81.36 and its 200 day moving average price is $68.95. The company’s market cap is $6.97 billion. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $89.45.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The company had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. During the same quarter in the previous year, the business posted ($1.05) EPS. The business’s quarterly revenue was up 82.9% compared to the same quarter last year. Analysts expect that Alnylam Pharmaceuticals will post ($5.19) earnings per share for the current year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.